Understand ctDNA, liquid biopsy vs tissue biopsy, and how blood-based cancer mutation testing fits into treatment decisions.
A practical guide to liquid biopsy for cancer: what ctDNA means, how blood-based mutation testing works, when it helps, when tissue biopsy is still needed, and how to interpret results with expert support.
Liquid Biopsy Guide for Cancer
Understand ctDNA, liquid biopsy vs tissue biopsy, and how blood-based cancer mutation testing fits into treatment decisions.
A practical guide to liquid biopsy for cancer: what ctDNA means, how blood-based mutation testing works, when it helps, when tissue biopsy is still needed, and how to interpret results with expert support.
500+
Genes Analyzed
24hr
Expert Callback
95%
Clinical Actionability
What is Liquid Biopsy?
Liquid biopsy is a blood-based test used in cancer care to study tumor DNA fragments that may be circulating in the bloodstream. These fragments are called circulating tumor DNA, or ctDNA. Instead of removing a fresh piece of tumor tissue, the lab analyzes plasma from a blood sample to look for cancer-related genetic changes.
Liquid biopsy does not replace tissue biopsy in every situation. Tissue is still important for diagnosis and tumor type confirmation. But when tissue is unavailable, repeat biopsy is risky, or cancer has changed after treatment, a ctDNA test can help doctors understand what may be driving the disease now.
Quick Facts
Blood
Sample
ctDNA / cfDNA
DNA Studied
Known Cancer
Used In
Expert Review
Needs
What Liquid Biopsy Can Detect
A single panel screens for every major class of cancer-driving genetic alteration.
Driver Mutations
Cancer-driving gene changes such as EGFR, KRAS, BRAF, PIK3CA, HER2, MET, RET, ROS1, NTRK, and others depending on the panel.
Resistance Mutations
New mutations that may explain why a treatment has stopped working, such as EGFR T790M/C797S, ESR1, MET amplification, or other escape signals.
Biomarker Signals
Some platforms report MSI-H, blood TMB, or related findings that may support immunotherapy discussions in selected cancers.
ctDNA Fraction
The level of tumor-derived DNA found in blood, which helps doctors judge how reliable a negative or low-signal report may be.
Liquid Biopsy vs. Tissue Biopsy — Comparison
Both tests can be useful. The right choice depends on your cancer type, stage, tissue availability, urgency, and what treatment question your oncologist is trying to answer.
Not sure which applies to you?
Get a Second OpinionWhat Is ctDNA — and How Does Testing Work?
ctDNA stands for circulating tumor DNA. As cancer cells grow, die, or respond to treatment, tiny fragments of tumor DNA can enter the bloodstream. A liquid biopsy separates plasma from blood, extracts this DNA, and uses sequencing to look for cancer-driving mutations.
A liquid biopsy report should always be read with the cancer diagnosis, imaging, treatment history, and ctDNA fraction. The report is powerful, but it is not a treatment plan by itself.
Tumor sheds ctDNA
Cancer cells release small DNA fragments into blood.
Blood draw
A sample is collected in tubes designed to preserve cfDNA.
NGS sequencing
The lab sequences selected cancer genes from plasma DNA.
Mutation report
Findings are matched to therapies, resistance, trials, or limitations.
How does liquid biopsy testing work?
Blood Sample Collection
A blood sample is collected in special tubes that help preserve circulating cell-free DNA for testing.
Plasma & cfDNA Extraction
The lab separates plasma from blood and extracts cell-free DNA, including any tumor-derived ctDNA.
ctDNA Sequencing
A targeted or comprehensive panel sequences cancer-related genes to look for mutations, fusions, copy number changes, and resistance markers.
Clinical Interpretation
The final report is interpreted with your cancer type, treatment history, imaging, ctDNA fraction, and tissue testing status.
Total turnaround: Educational resource from sample collection to final report. Our team calls back within 2 hours of your enquiry to guide you through the process.
Why Liquid Biopsy Matters
Liquid biopsy matters because cancer changes over time. A blood-based ctDNA test can sometimes show what is driving the cancer now, especially after treatment stops working.
Blood
sample instead of repeat tissue procedure
ctDNA
tumor DNA fragments analyzed from plasma
Context
needed to interpret every result correctly
It can reduce the need for repeat procedures
When tumor tissue is difficult to access, blood-based testing can provide molecular clues without a new surgical biopsy.
It can explain resistance
Cancer can evolve under treatment pressure. ctDNA testing may detect new resistance mutations that were absent at diagnosis.
It can guide smarter next steps
A positive finding may support targeted therapy or trial matching, while a negative report may point toward tissue testing or repeat evaluation.
It needs careful interpretation
Panel scope, ctDNA fraction, cancer type, and prior treatment all affect what a report can and cannot prove.
Got your report? We'll walk you through it.
Benefits of Liquid Biopsy
Every benefit below translates into a more informed, faster, and more personal treatment decision.
Less Invasive
Uses a blood sample, which is easier for many patients than repeat tissue biopsy.
Useful When Tissue Is Limited
Helpful when archived biopsy tissue is insufficient, old, or unavailable for sequencing.
Tracks Tumor Evolution
Can reveal new mutations that emerge after chemotherapy, targeted therapy, or endocrine therapy.
Supports Precision Oncology
May identify targeted therapy, immunotherapy, or trial-relevant findings.
Faster Practical Pathway
A blood draw can often be coordinated faster than scheduling a new biopsy procedure.
Second Opinion Friendly
Existing reports from major platforms can be reviewed without automatically repeating the test.
See exactly which of these benefits apply to your case.
Other Genomic Tests You May Need
Book Liquid Biopsy
Transactional page for ctDNA test booking and report review
NGS Testing
Comprehensive cancer gene profiling
Tumor DNA Sequencing
Tissue-based somatic profiling
Not sure which test applies to you?
Get a second opinion or consult our multidisciplinary tumor board to confirm the right genomic test for your diagnosis.
Liquid Biopsy Applies Across Cancer Types
Lung Cancer
Commonly used for EGFR and other targetable or resistance markers in advanced NSCLC.
Breast Cancer
May help identify ESR1, PIK3CA, HER2, BRCA-related, and resistance findings.
Colorectal Cancer
Can support RAS/BRAF, HER2, MSI, and resistance discussions when tissue is limited.
Prostate Cancer
May detect DNA repair alterations and other findings relevant to later-line options.
Frequently Asked Questions
Answers for both first-time patients and those who already have a Liquid Biopsy report in hand.
What is liquid biopsy in simple words?
Liquid biopsy is a cancer test done from a blood sample. It looks for tiny fragments of tumor DNA, called ctDNA, that may be present in the bloodstream. The goal is to understand cancer mutations without always needing a fresh tissue biopsy.
What is ctDNA?
ctDNA means circulating tumor DNA. These are small pieces of DNA released by cancer cells into the blood. Liquid biopsy tests analyze ctDNA to look for mutations that may affect targeted therapy, resistance, immunotherapy discussions, or clinical trial options.
Is liquid biopsy better than tissue biopsy?
Neither is universally better. Liquid biopsy is easier and useful when tissue is unavailable or repeat biopsy is risky. Tissue biopsy is still important for diagnosis, cancer type confirmation, and cases where a negative blood test may be unreliable because the tumor sheds little ctDNA.
What does a negative liquid biopsy mean?
A negative liquid biopsy means the tested blood sample did not show reportable mutations. It does not always mean the tumor has no mutations. Low ctDNA shedding, panel limits, or timing can make a result falsely negative, so tissue testing may still be advised.
When is liquid biopsy commonly used?
It is commonly used in advanced cancer, when tissue biopsy is not feasible, when older tissue is insufficient for NGS, when cancer progresses after treatment, or when doctors need to check resistance mutations quickly.
Can liquid biopsy detect early cancer?
Some blood-based cancer detection tests are being developed for screening, but most clinical liquid biopsy tests used in oncology today are for known cancer mutation profiling, treatment selection, and resistance monitoring.
Why does ctDNA fraction matter?
ctDNA fraction shows how much tumor-derived DNA was detected in the blood sample. If ctDNA fraction is very low, a negative result may be less reliable and should be interpreted carefully with imaging, diagnosis, and treatment history.
Do I need a doctor to interpret a liquid biopsy report?
Yes. Liquid biopsy reports include mutations, variants of unknown significance, therapy associations, and limitations. A molecular oncologist or tumor board can explain what is actionable, what is uncertain, and what should be done next.
Still have questions about your Liquid Biopsy report or results?
